John Bridgewater trained in Oxford and University College London qualifying in 1986. He further trained in Medical Oncology at the Middlesex, Royal Free, Mount Vernon and Royal Marsden Hospitals. He obtained a PhD thesis in gene therapy at the Institute of Cancer Research 1996. He was appointed as a Senior Lecturer in Medical Oncology at UCL in 1999. He also visits the North Middlesex and Princess Alexandra Harlow hospitals.
John Bridgewater specialises in gastrointestinal oncology, with a particular interest in biliary tract cancers and carcinomas of unknown primary origin. He leads the National Cancer Research Institute subgroup in bilary tract malignancy and is actively involved in the research portfolio. He is also active in trials across the gastrointestinal portfolio and is a member of the European Organisation for Research and Treatment of Cancer. He has a laboratory programme investigation Carcinoma of Unknown Primary based at the UCL Cancer Institute.
Bridgewater JA, Springer CJ, Knox RJ, Minton N, Michael NP and Collins MKL. Expression of bacterial nitroreductase in mammalian cells renders them selectively sensitive to killing by CB1954. Eur J Cancer (1995) 31A: 2362-70.
Bridgewater JA, Knox RJ, Pitts JD, Collins MK and Springer CJ. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell permeable metabolite. Human Gene Therapy (1997) 8: 709-17.
Bridgewater JA, Nelstrop AE, Rustin GJS, Gore ME, McGuire WP and Hoskins WJ. Comparison of clinical and CA125 responses in patients with epithelial Ovarian cancer treated with platinum or paclitaxel. J Clin Oncol (1999) 17(2):501-8
Lia van Zuylen, John Bridgewater, Alex Sparreboom, Ferry A.L.M. Eskens, Peter de Bruijn, Ivo Sklenar, Andre S.T. Planting, Les Choi, Douglas Bootle, Christian Mueller, Jonathan A. Ledermann, and Jaap Verweij. Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/Leucovorin in Metastatic Colorectal Cancer. Clin Cancer Res: 2004 Mar 15;10(6):1949-55
Thierry André, Corrado Boni, Lamia Mounedji-Boudiaf, Mathilde Navarro, Josep Tabernero, Thamas Hickish, Clare Topham, Marta Zaninelli, Philip Clingan, John Bridgewater, Isabelle Tabah-Fisch, Aimery de Gramont. Oxaliplatin, 5 Fluorouracil and Leucovorin in Adjuvant Colon Cancer: Results of the International Randomized MOSAIC Trial. New Eng J Med 2004 Jun 3;350(23):2343-51
Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2006 Mar 1;12(5):1577-84
Samuel Aballea, Jeremy V.M. Chancellor, Maria Raikou, Michael F. Drummond, Milton C. Weinstein, Sophia Jourdan, John Bridgewater. Cost-Effectiveness Analysis of Oxaliplatin Compared With 5-Fluorouracil/Leucovorin in Adjuvant Treatment of Stage III Colon Cancer in the US. Cancer 2007;109:1082–9.
Stebbing J, Harrison M, Glynne-Jones R, Bridgewater J, Propper D. A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). Br J Cancer. 2008 Feb 26;98(4):716-9.
Bridgewater J R van Laar R A Floore A and Van’t Veer L. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer (2008) 98, 1425 – 1430